why choose us

Clinical Trials Search

Showing 17,220 of 132,963 result(s)
DMID 21-0041; Influenza CVD 59000

Status: Completed

Condition: Influenza

Interventions:

Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization

Date: 2022-12-16

Pilot of Peers Enhancing Engagement for Pain Services

Status: Completed

Condition: Chronic Pain

Interventions: Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches;treatments

Date: 2022-12-16

A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder

Status: Completed

Condition: Binge-eating Disorder

Interventions: oxytocin nasal spray

Date: 2022-12-16

UPURS Trial for Patient-centered Management of Symptomatic Obstructing Stones

Status: Completed

Condition: Ureteral Stone

Interventions: Upfront ureteroscopy

Date: 2022-12-16

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Status: Completed

Condition: Carcinoma, Non-Small-Cell Lung

Interventions: Dexamethasone will be administered orally.

Date: 2022-12-16

Confirmation of Diet as a Treatment for Gulf War Illness

Status: Completed

Condition: Gulf War Syndrome

Interventions: This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while

Date: 2022-12-16

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19

Status: Completed

Condition: Post COVID-19 Condition

Interventions: The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in mana

Date: 2022-12-16

Comparison of Two Pulmonary Embolism Treatments

Status: Completed

Condition: Pulmonary Embolism Acute

Interventions: Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)

Date: 2022-12-16

A Study of Adjuvant Pembrolizumab;Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010;KEYVIBE-010)

Status: Completed

Condition: Melanoma

Interventions: Co-formulation of pembrolizumab 200 mg;20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations

Date: 2022-12-16

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Status: Completed

Condition: Non-Hodgkin Lymphoma

Interventions: Undergo blood sample collection

Date: 2022-12-16